Diana Ernst, RPh

Editorial Director https://www.clinicalpainadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Migraine & Headache

Galcanezumab Benefits Patients With Treatment-Resistant Migraine in Phase 3 Trial

Diana Ernst, RPh

August 8, 2019

Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.

Chronic Pain

Hydromorphone Injection Recalled Due to Presence of Sulfite

Diana Ernst, RPh

July 8, 2019

While no adverse events have been reported to date, the use of this product could potentially cause serious adverse reactions.

General Pain

FDA Draft Guidance Seeks to Improve Drug Abuse, Dependence Information in Labeling

Diana Ernst, RPh

July 3, 2019

The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.

General Pain

Review Investigates Adverse Effects of Cannabidiol

Diana Ernst, RPh

July 1, 2019

The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.

Opioid Addiction

Risk for Prolonged Use With Tramadol vs Other Short-Acting Opioids Examined

Diana Ernst, RPh

May 16, 2019

Compared with other short acting opioids, patients prescribed tramadol may be at greater risk of prolonged use following surgery, according to a study published in The BMJ.

General Pain

Injectable Pain Med Recalled Due to Possible Microbial Contamination

Diana Ernst, RPh

May 2, 2019

A recall of 1 lot of Ketorolac Tromethamine Injection 60mg/2mL (30mg/mL) has been initiated by Sagent Pharmaceuticals following the discovery of microbial growth during a routine simulation of the manufacturing process. Concerns over the possible introduction of microorganisms into the product led the Company to issue the recall to the user level. The product is…

Migraine & Headache

Fremanezumab Cluster Headache Development Program Discontinued

Diana Ernst, RPh

April 25, 2019

Teva announced that the ENFORCE phase 3 program for fremanezumab in the treatment of cluster headaches will be discontinued following results from a futility analysis.

Migraine & Headache

FDA to Review IV-Administered Eptinezumab for Migraine Prevention

Diana Ernst, RPh

April 24, 2019

The FDA has accepted for review the Biologics License Application for eptinezumab (Alder BioPharmaceuticals), an investigational CGRP inhibitor for migraine prevention.

Post-Surgical Pain

Loteprednol Etabonate Now Available for Postoperative Ocular Pain

Diana Ernst, RPh

April 3, 2019

Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.

First App Launched to Identify Drug Shortages

Uncategorized

FDA Updates REMS for Transmucosal Immediate-Release Fentanyl Products

Diana Ernst, RPh

March 28, 2019

The Food and Drug Administration has announced that the Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) medications has been updated to better ensure the safe use of these products.

Next post in Uncategorized